- WHATS NEW?
- Low HDL-C: key predictor of metabolic syndrome in African American women
- Meta-analysis shows positive effects of nicotinic acid on CV events
- Low HDL-C: increasing problem in adolescents
- Niacin restores vasoprotective effects of HDL in type 2 diabetes
- Low HDL-C is common despite statin therapy
- Insights from VOYAGER on statin-induced HDL response
- rHDL attenuates platelet hyperreactivity in type 2 diabetics
- HATS, FATS and AFREGS Metsyn analysis highlights need to target HDL
- Analysis of ARBITER 6-HALTS: HDL Forum Editor, Professor Philip Barter
- New study shows plaque regression with nicotinic acid on top of statin therapy
> News Archive <
Niacin/laropiprant plus simvastatin shows additive lipid-modifying effects
Extended-release niacin/laropiprant co-administered with simvastatin improved overall lipid control in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
More Detail... Download article...
Efficacy of new niacin/simvastatin combination product
A study in more than 600 patients with dyslipidaemia showed that a new combination extended release niacin/simvastatin product was effective and well-tolerated.
More Detail... Download article...
HDL protective against cardiac rhythm disturbances
Low HDL cholesterol levels are associated with increased risk of developing cardiac arrhythmia in patients with non-ST elevation acute coronary syndromes.
More Detail... Download article...
Data from FIELD: Dyslipidaemia an important discriminator of cardiovascular risk
Marked dyslipidaemia, including low HDL cholesterol and elevated triglycerides, is a key factor influencing cardiovascular risk in patients with type 2 diabetes and features of the metabolic syndrome.
More Detail... Download article...
Niacin impacts favourably on HDL properties in metabolic syndrome
Extended-release niacin has a beneficial effect on HDL vasoprotective qualities in people with the metabolic syndrome.
More Detail... Download article...
Novel therapy increases HDL cholesterol
Administration of KC706, an oral p38 MAP kinase inhibitor, increases HDL cholesterol levels in patients with mixed dyslipidaemia.
More Detail... Download article...
New Joint European Society?s guidelines on CVD prevention
HDL cholesterol is now incorporated in the interactive version of SCORE, HeartScore, for cardiovascular risk assessment.
More Detail... Download article...
HDL cholesterol and acute coronary syndromes
Prognosis after an acute coronary syndrome is worse in patients with low HDL cholesterol levels, highlighting the need to investigate the benefit of HDL cholesterol-raising therapy.
More Detail... Download article...
Anti-inflammatory role of HDL cholesterol: data from the ATTICA study
Results from the ATTICA study show an inverse relationship between HDL cholesterol and inflammatory markers, including C-reactive protein.
More Detail... Download article...
Low HDL cholesterol increases the risk of cardiovascular events or stroke despite statin therapy
Low HDL cholesterol significantly increases the risk of an event by 24%, in patients who failed to achieve LDL cholesterol targets despite statin use.
More Detail... Download article...
Combination nicotinic acid/laropiprant: effective with reduced flushing
Extended release (ER) nicotinic acid plus laropiprant, a PGD2 antagonist, provided effective overall lipid control with significantly less flushing than reported with ER nicotinic acid alone.
More Detail... Download article...
Promising data on new CETP inhibitor
MK-0859, a new cholesteryl ester transfer protein (CETP) inhibitor, produces effective dose-dependent lipid-lowering and is well tolerated.
More Detail... Download article...
HDL may protect against development of hypertension
Higher HDL cholesterol levels may protect against the development of hypertension in middle-aged men.
More Detail... Download article...
HDL cholesterol: an independent risk factor for progression of subclinical cardiovascular disease
Data from the Atherosclerosis Risk in Communities (ARIC) study show
that HDL cholesterol may be an important modifiable risk factor for the
progression of subclinical cardiovascular disease, as reported at ACC
2007.
More Detail... Download article...
Low HDL cholesterol is common in patients with non-ST-segment elevation acute coronary syndromes
Data from the CRUSADE initiative show that more than 50% of patients
with non-ST-segment elevation acute coronary syndromes have low HDL
cholesterol (<40 mg/dL), as reported at ACC 2007.
More Detail... Download article...
Over 70% of statin-treated patients have low HDL cholesterol
Two-thirds of statin-treated patients with or at risk of coronary heart
disease have low HDL cholesterol. This patient group represents a large
unmet opportunity for further CHD prevention.
More Detail... Download article...
Disappointing results with major studies with torcetrapib
Results from ILLUSTRATE and RADIANCE failed to demonstrate any benefit
on progression of atherosclerosis with torcetrapib administered in
combination with atorvastatin, despite substantial increases in HDL
cholesterol.
More Detail... Download article...
Results of METEOR Trial: rosuvastin in low-risk patients
Rosuvastatin slowed progression of atherosclerosis at 2 years in people
with early signs of carotid artery disease and at low-risk of coronary
heart disease (CHD).
More Detail... Download article...
HDL infusion improves plaque characteristics: results of ERASE trial
Short-term infusion of CSL-111, a reconstituted HDL, produced
significant improvement in plaque characteristics compared with placebo.
More Detail... Download article...
Mixed results with LY518674, novel therapy for lipid disorders
LY518674, a novel, potent peroxisome proliferator- activated receptor
alpha (PPAR-alpha) agonist, showed no advantages compared with
fenofibrate, in clinical studies.
More Detail... Download article...
HDL a key focus of EAS Congress, June 2007
The relevance of HDL to atherosclerosis is a major emphasis of the
upcoming 76th Congress of the European Atherosclerosis Society,
Helsinki, June 10-13, 2007. There will be a plenary session and an
official EAS HDL Satellite Symposium focusing on HDL and cardiovascular
disease. For further information, see the meeting website at www.eas2007.fi
Low apolipoproteinA-II is a predictor of coronary heart disease
Apolipoprotein II, the second main protein in HDL, is inversely related
to risk of coronary heart disease, according to new data presented at
the American Heart Association Scientific Sessions.
More Detail... Download article...
Should measurement of ApoB/ApoA1 ratio be incorporated into clinical guidelines?
The ratio of apolipoprotein B/apolipoprotein A-I (i.e., atherogenic to
atheroprotective lipoproteins) was the strongest predictor of
cardiovascular risk, according to pooled analyses of two recent major
statin studies, presented at the American Heart Association Scientific
Sessions.
More Detail... Download article...
High HDL cholesterol improves outcome following drug-eluting stent implantation
High HDL cholesterol levels are protective against major adverse
cardiac events within one year of drug-eluting stent implantation,
according to data presented at the American Heart Association
Scientific Sessions.
More Detail... Download article...
Apolipoprotein A-I mimetic improves HDL anti-inflammatory function
Administration of the apolipoprotein A-I mimetic peptide D-4F improves
anti-inflammatory activity of HDL in patients at high risk of coronary
heart disease, suggesting therapeutic potential for attenuation of
atherosclerosis.
More Detail... Download article...
First report of SR-B1 mutation in man influencing HDL cholesterol levels
Researchers from the Academic Medical Center, Amsterdam, The
Netherlands presented the first evidence of a scavenger receptor class
B1 (SR-B1) mutation in man. SR-B1 is a hepatic receptor that promotes
selective uptake and removal of HDL from the plasma, and is therefore
important in protecting against atherosclerosis.
More Detail... Download article...
Low HDL cholesterol is a predictor of stroke
Data from the Stroke Prevention by Aggressive Reduction in Cholesterol
Levels (SPARCL) study show that low HDL cholesterol is an important
predictor of risk of stroke in patients with recent stroke or transient
ischaemic attack.
More Detail... Download article...
Reconstituted HDL improves endothelial function in type 2 diabetes
Infusion of reconstituted HDL exerts direct beneficial effects on the
arterial wall in patients with type 2 diabetes, providing support for
therapeutic strategies that increase the vasodilatory properties of HDL.
More Detail... Download article...
STRADIVARIUS: Rimonabant fails to slow atherosclerosis progression
Rimonabant has failed to show any benefit on progression of atherosclerosis in STRADVIVARIUS (Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabant-The Intravascular Ultrasound Study) in patients with abdominal obesity and coronary artery disease (CAD). The study was presented by Dr Steve Nissen, Cleveland Clinic, Ohio during the American College of Cardiology 2008 Scientific Sessions, and published simultaneously in the Journal of the American Medical Association.
Results from PERISCOPE: pioglitazone slows atherosclerosis
Data from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial reported at Scientific Sessions of the American College of Cardiology 2008 Meeting suggest that pioglitazone can prevent atherosclerosis progression and produce clinically meaningful changes in cardiovascular risk factors including high-density lipoprotein (HDL) cholesterol in patients with type 2 diabetes. The results were reported by Dr Steve Nissen, Cleveland Clinic, Ohio and lead author of the paper.
High-density lipoprotein cholesterol - a link to memory?
A low level of high-density lipoprotein (HDL) cholesterol in middle-aged people is associated with poor memory, according to a recent study. The study was reviewed in an accompanying editorial by Professor John Chapman, HDL Forum Editor and Dr Anatol Kontush, INSERM, Hopital de la Pitie,
Singh-Manoux A, Gimeno D, Kivimaki M et al. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife. The
More Detail... Download article...
CETP genotypes, HDL cholesterol and coronary risk
A meta-analysis including data from nearly 114,000 healthy subjects and over 27,000 coronary cases reported in the Journal of the American Medical Association showed an association between three genotypes of cholesteryl ester transfer protein (CETP), moderate increases in high-density lipoprotein (HDL) cholesterol and coronary risk. These data suggest that the presence of these CETP genetic variants may confer slightly reduced coronary risk. The study was reviewed by HDL Forum Editor, Professor John Chapman.
Thompson A, Di Angelantonio E, Sarwar N et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008;299:2777-88.
More Detail... Download article...
Niacin and HDL cholesterol: new insights
Niacin (nicotinic acid) is the most effective agent currently available for raising plasma levels of high-density lipoprotein (HDL) cholesterol. However, to date little is known about the mechanism of its effect in people with dyslipidemia, ideal targets for therapy. Data from a study by researchers at
Lamon-Fava S, Diffenderfer MR, Barrett PHR et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (
More Detail... Download article...
New insight into apolipoprotein A-I structure in high-density lipoprotein
A recent study provides new information that will further understanding of HDL structure, metabolism and function. Results of this study were discussed by HDL Forum Editors Professors Kerry-Anne Rye and John Chapman.
Silva RAGD, Huang R, Morris J et al. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci 2008;105:12176-81.
More Detail... Download article...
Increasing prevalence of low HDL cholesterol/elevated triglycerides highlights need for more comprehensive lipid control
Data presented at the American Heart Association Annual Scientific Sessions, New Orleans 2008 underscore an urgent need for monitoring and managing high density lipoprotein (HDL) cholesterol and triglycerides. Evidence from the National Health and Nutrition Examination Survey (NHANES) show that the percentage of adults with the combination of low HDL cholesterol and elevated triglycerides doubled over the last 30 years, possibly linked to rising obesity rates.
More Detail... Download article...
New therapeutic agents for raising HDL cholesterol: first clinical data
Early clinical data were presented on two new therapeutic possibilities - RVX-208 and autologous delipidated HDL - for raising high density lipoprotein (HDL) cholesterol at the American Heart Association Annual Scientific Sessions, New Orleans 2008.
More Detail... Download article...
Ethnic differences in antipsychotic effects on HDL
Evidence from the US CATIE Schizophrenia Study suggests that there may be underlying racial differences in how antipsychotic treatment influences high density lipoprotein (HDL) cholesterol. In this trial, white subjects who took perphenzaine and non-whites who took ziprasidone showed an increase in HDL cholesterol levels. These findings may have implications for choice of medication in patients at high cardiometabolic risk.
More Detail... Download article...
Reconstituted HDL lowers plaque lipids, macrophage size and measures of inflammation
Researchers from the Baker IDI Heart and Diabetes Institute,
More Detail... Download article...
Low HDL cholesterol: an important risk factor in heart attack patients
Data from the American Heart Association’s Get With The Guidelines study highlight the need for improvement in the management of low high density lipoprotein (HDL) cholesterol. More than 50% of patients hospitalised for heart attack had an HDL cholesterol value less than 40 mg/dL. The study was published in the January issue of The American Heart Journal.
More Detail... Download article...
INTERHEART: More than 80% of South Asians had low HDL cholesterol
A report from the INTERHEART study highlights the high prevalence of low plasma levels of high density lipoprotein (HDL) cholesterol in South Asians compared with other Asians. Over 80% of subjects, with or without previous heart attack, had a low level of HDL cholesterol (<40 mg/dl in men and <50 mg/dL in women). These data emphasise the need for targeted intervention amongst this group.
More Detail... Download article...
Favourable changes in HDL cholesterol and triglyceride levels: Framingham analysis
Data from the Framingham Offspring Study suggest improvements in dyslipidemia, notably an increase in high density lipoprotein (HDL) cholesterol and decrease in triglycerides over the period 1991-2001. This was despite an overall increase in body mass index (BMI). The data were reviewed by HDL Forum Editor Kerry-Anne Rye.
More Detail... Download article...
News from ACC 2009: Benefits of combination fenofibric acid/rosuvastatin in mixed dyslipidemia
29 March, 2009 - Combination therapy with fenofibric acid and rosuvastatin calcium (135 mg/5 mg) provided significantly improved, comprehensive lipid management over either monotherapy in patients with mixed dyslipidemia. Notably, high density lipoprotein (HDL) cholesterol levels were doubled compared with rosuvastatin alone. The study was reported at the American
News from ACC 2009: HDL cholesterol: an important component of residual heart disease risk in statin-treated patients
31 March 2009 - Analysis based on a systematic review of statin trials (476,917 person-years of follow-up) demonstrated that a low level of high density lipoprotein (HDL) cholesterol is an important contributor to residual coronary risk in statin-treated patients. Results were reported at the American
HDL cholesterol response to bezafibrate influences long-term mortality risk
Analysis of 16-year mortality data from the Bezafibrate Infarction Prevention (BIP) study showed that the extent of high-density lipoprotein (HDL) cholesterol raising associated with bezafibrate treatment influenced long-term survival benefits after discontinuation of therapy. The study was reviewed by HDL Forum Editor Professor Philip Barter.
More Detail... Download article...
HDL cholesterol: new light on stroke risk?
Findings from a meta-analysis of statin studies suggest a role for systematic measurement of high-density lipoprotein (HDL) cholesterol in stroke patients. This is not routinely undertaken at present. The data are reviewed by HDL Forum Editor Professor Philip Barter in this commentary.
More Detail... Download article...
Raising HDL: potential beyond atherosclerosis in managing type 2 diabetes?
Raising levels of high-density lipoprotein (HDL) cholesterol may improve glucose tolerance in patients with type 2 diabetes, according to a new study published in Circulation. HDL Forum Editor Professor Kerry-Anne Rye reviews and comments on this study.
More Detail... Download article...
Asia Pacific region: Smoking reduces cardioprotective effects of HDL cholesterol
New data from the Asia Pacific Cohort Studies Collaboration indicates that smoking mitigates the protective effects of high-density lipoprotein (HDL) cholesterol on coronary risk.
More Detail... Download article...
News from American Diabetes Association Scientific Sessions 2009
HDL cholesterol raising with combination fenofibric acid/rosuvastatin in mixed dyslipidemia
Analysis of two phase 2 studies involving 480 patients with type 2 diabetes and mixed dyslipidemia showed that this treatment combination improved achievement of American Diabetes Association (ADA) target lipid levels compared with those taking rosuvastatin monotherapy. In particular, patients receiving combination treatment (fenofibric acid plus 5 mg rosuvastatin) had a 25% increase in high-density lipoprotein (HDL) cholesterol compared with 17% on rosuvastatin monotherapy (p<0.05).
More Detail... Download article...
Low HDL: associated with subclinical atherosclerosis in early childhood
A low plasma level of high-density lipoprotein (HDL) cholesterol was independently associated with increased arterial wall thickness, a marker for subclinical atherosclerosis, according to a study reported by Atherosclerosis Thrombosis & Vascular Biology. In addition, higher levels of blood pressure and asymmetric dimethylarginine (ADMA), an endogenous inhibitor of production of nitric oxide, which is important in maintaining arterial endothelial integrity and inhibiting platelet aggregation, leukocyte adhesion and smooth muscle proliferation, were associated with greater arterial wall thickness. These data suggest that mechanisms that alter arterial structure are present at a very early age. The report was reviewed by HDL Forum Editor Professor Philip Barter.
More Detail... Download article...
HDL cholesterol, stroke and diabetes
Low levels of high-density lipoprotein (HDL) cholesterol increase the risk for stroke in elderly type 2 diabetic patients, according to recent results of the Japan Cholesterol and Diabetes Mellitus study. The study was reviewed by HDL Forum Editor Professor Philip Barter.
More Detail... Download article...
High HDL cholesterol improves long-term outcome after PCI
High levels of high-density lipoprotein (HDL) cholesterol before percutaneous coronary intervention can reduce the risk of post-procedural myocardial infarction and improve long-term outcome, according to the results of a study at the West German Heart Center, University Hospital Essen, Germany.
More Detail... Download article...
Low HDL-C increasingly prevalent in China
New data highlight the impact of economic development in
More Detail... Download article...
Apolipoprotein ratios are more informative about MI risk
Findings from the International Studies of Infarct Survival (ISIS) Collaborators indicate that the measuring the ratio of apolipoproteins (apolipoprotein B to apolipoprotein A1 as in HDL particles) could be more useful in predicting risk for MI.
More Detail... Download article...
AFCAP/TexCAPS: Additional benefit of raising HDL cholesterol in statin-treated patients
In a post-hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), lovastatin-treated patients with both substantially reduced low-density lipoprotein cholesterol and an increase in high-density lipoprotein HDL) cholesterol ³7.5% showed the greatest reduction in acute major coronary events (AMCEs).
More Detail... Download article...
HDL quality and quantity both relevant for atheroprotective functions
Myeloperoxidase-catalyzed oxidation of HDL not only leads to the loss of atheroprotective cholesterol efflux activities but also to the generation of pro-inflammatory HDL, according to new data reported in the Journal of Biological Chemistry. This could impact on the risk for development of cardiovascular disease.
More Detail... Download article...
ARBITER 6-HALTS
ARBITER 6-HALTS shows that raising HDL cholesterol regresses atherosclerosis in high-risk patients at LDL cholesterol goal.
More Detail... Download article...
Oxford Nicotinic acid Trial
This trial provides the first direct evidence that raising HDL cholesterol with nicotinic acid regresses atherosclerosis within 12 months in high-risk statin-treated patients with low HDL cholesterol.
More Detail... Download article...
ARBITER 2 and 3 trials
ARBITER 2 showed that combination niacin-statin treatment led to stabilisation of atherosclerosis in CHD patients with low HDL cholesterol. Treatment with statin alone resulted in progression of atherosclerosis.
More Detail... Download article...
HATS: HDL Atherosclerosis Treatment Study
In HATS, treatment with the combination of niacin plus simvastatin produced significant angiographic regression of coronary artery stenosis versus placebo.
More Detail... Download article...
VA-HIT
In VA-HIT, raising HDL cholesterol by 6% with gemfibrozil was associated with a significant 22% reduction in major coronary events, the primary endpoint.
More Detail... Download article...
Coronary Drug Project
15-year follow-up data from the Coronary Drug Project (nearly 9 years after the end of the study) showed that patients in the niacin group had a significant reduction in total and coronary heart disease mortality.
More Detail... Download article...
FATS: Familial Atheorsclerosis Treatment Study
In FATS, combination niacin-colestipol treatment raised HDL cholesterol by 43%, and was associated with significantly higher prevalence of regression of atherosclerotic coronary lesions versus conventional therapy.
More Detail... Download article...
CLAS: Cholesterol Lowering Atherosclerosis Study
CLAS: One of the first imaging studies to show that raising HDL cholesterol with niacin could lead to regression of atherosclerosis.
More Detail... Download article...
COMPELL
Combination treatment with low to moderate doses of niacin plus statin provided comprehensive lipid control, superior to potent statin monotherapy or combination statin-ezetimibe therapy.
More Detail... Download article...
SEACOAST
Combination ER niacin plus simvastatin led to significant improvements in the management of non-HDL-C, LDL-C, HDL-C and triglycerides over simvastatin monotherapy.
More Detail... Download article...
ACCORD Lipid Treatment Arm
Does combination treatment with fenofibrate plus simvastatin targeting HDL cholesterol and triglycerides provide outcomes benefits over simvastatin monotherapy in type 2 diabetes patients at LDL cholesterol goal?
More Detail... Download article...
AIM-HIGH
Does adding ER niacin to simvastatin in high-risk patients optimally managed for LDL cholesterol provide outcomes benefits over simvastatin monotherapy?
More Detail... Download article...
HPS2-THRIVE
Does raising HDL cholesterol with the combination of niacin/laropiprant provide additional cardiovascular risk reduction in high-risk patients with optimally managed LDL cholesterol?
More Detail... Download article...
ILLUMINATE
A review of findings from the ILLUMINATE trial
More Detail... Download article...
DEFINE: CETP inhibition with anacetrapib
DEFINE: Investigating the lipid-modifying efficacy and safety of anacetrapib in high-risk patients at LDL cholesterol goal
More Detail... Download article...
Dalcetrapib: 48 week trial
Longer-term lipid-modifying efficacy with dalcetrapib with no evidence of clinically relevant changes in blood pressure or aldosterone or incraese in adverse events.
More Detail... Download article...
HDL and atherosclerosis
HDL and atherosclerosis: an overview
More Detail... Download article...
HDL cholesterol and cardiovascular risk
HDL cholesterol and cardiovascular risk: an overview of population studies and trials
More Detail... Download article...
Raising HDL cholesterol: therapeutic considerations
Raising HDL cholesterol: an overview of therapeutic considerations
More Detail... Download article...
ER Niacin-laropiprant vs. ER-niacin
Comparative flushing profile of ER-niacin/laropiprant versus ER-niacin
More Detail... Download article...
> HDL Biology Archive <
High-density lipoprotein (HDL) protects against atherosclerosis by upregulation of anti-inflammatory and anti-oxidant pathways
HDL Forum Editor Professor Kerry-Anne Rye highlights new data suggesting an additional mechanism by which high-density lipoprotein (HDL) protects against atherosclerosis, reported by NM Gharavi and co-workers in Arteriosclerosis, Thrombosis and Vascular Biology.
Defective ABCA1 increases coronary risk in familial low high-density lipoprotein (HDL) cholesterol
HDL Forum Editor Professor Kerry-Anne Rye discusses a study investigating the relationship between familial low high-density lipoprotein (HDL) cholesterol, coronary risk and ABCA1, reported by A Soro-Paavonen and co-workers in the Journal of Lipid Research.
Antiatherogenic effects of high-density lipoprotein (HDL) cholesterol during the perimenopause
HDL Forum Editor Professor Philip Barter comments on findings suggesting that the antiatherogenic effects of high-density Lipoprotein (HDL) cholesterol may decrease around the age of menopause. These results from the Los Angeles Atherosclerosis Study were published on-line in Atherosclerosis.
Regular aerobic exercise increases high-density lipoprotein (HDL) cholesterol
HDL Forum Editor Professor Philip Barter highlights a meta-analysis by S Kodama and co-workers which confirms the benefit of regular aerobic exercise on raising high-density lipoprotein (HDL) cholesterol. These data re-enforce recommendations for increasing levels of activity as a cardioprotective strategy. The analysis was reported in Archives of Internal Medicine.
Low high-density lipoprotein (HDL) cholesterol linked to abnormal sleep
HDL Forum Editor Professor John Chapman notes interesting data from the Nurses' Health Study which support an association between low high-density lipoprotein (HDL) cholesterol and abnormalities in sleep habits. The analysis was reported in Diabetes Care.
Low level of high-density lipoprotein (HDL) cholesterol predictive of outcome after cardiac stenting
HDL Forum Editor Professor John Chapman comments on evidence that a low level of high-density lipoprotein (HDL) cholesterol is an independent predictor of long-term outcome after cardiac stenting. The study was published in Thrombosis and Haemostasis.
Raising high-density lipoprotein (HDL) cholesterol in patients at LDL goal: new study
HDL Forum Editor Professor Philip Barter comments on an interesting and important new lipid trial in patients with persistently low levels of high-density lipoprotein (HDL) cholesterol: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol-6-HDL and LDL Treatment Strategies in Atherosclerosis (ARBITER 6-HALTS).
Changes in apolipoprotein A-I impair its antiatherogenic function
HDL Forum Editor Professor Kerry-Anne Rye discusses experimental data from a study by A Hoang and co-workers, published in Diabetologia. These data suggest that modification of apolipoprotein A-I (apoA-I), the main apolipoprotein in high-density lipoprotein (HDL), can impair its antiatherogenic function and contribute to increased cardiovascular risk.
Meta-analysis supports raising high-density lipoprotein (HDL) cholesterol
HDL Forum Editor Professor Philip Barter highlights findings from a meta-analysis of interventions for raising high-density lipoprotein (HDL) cholesterol by IM Singh and researchers, published in the Journal of the American Medical Association.
New data support the use of total/HDL cholesterol ratio to assess stroke risk
HDL Forum Editor Professor M John Chapman discusses a recent meta-analysis on cholesterol and vascular risk, published by the Prospective Studies Collaboration, Oxford, in The Lancet, December 1, 2007.
Anacetrapib, a new CETP inhibitor, raises high-density lipoprotein (HDL) cholesterol without affecting blood pressure
HDL Forum Editor Professor Philip Barter discusses new data on anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor published by Rajesh Krishna and co-workers in The Lancet, December 2007.
Statin therapy does not eliminate cardiovascular risk due to low high density lipoprotein cholesterol in diabetes patients
HDL Forum Editor Dr Anthony Wierzbicki discusses findings from a new meta-analysis from the Cholesterol Treatment Trialists' (CTT) Collaborators, published in The Lancet, January 11, 2008. Diabetes patients with a low level of high density lipoprotein (HDL) cholesterol remain at increased cardiovascular risk, despite statin therapy.
Raising high density lipoprotein: need to take account of functionality?
Are very high levels of high-density lipoprotein (HDL) cholesterol and very large HDL particles associated with increased coronary risk? These are the findings from an analysis of data from the IDEAL (Incremental Decrease in End Points through Aggressive Lipid Lowering) trial and EPIC (European Prospective Information into Cancer and Nutrition) Norfolk Cohort, discussed by HDL Forum Editor Professor Kerry-Anne Rye. The analysis was published in the Journal of the American College of Cardiology on 5 February 2008.
Apolipoprotein A-II is atheroprotective
Apolipoprotein A-II, a component of high-density lipoprotein (HDL), was shown to be anti-atherogenic in one of the largest studies to date, based on the EPIC-Norfolk cohort. HDL Forum Editor0 Professor Kerry-Anne Rye discusses these data and their implications.
Corporate sponsor
